Market Data 
Markets
Replies to post #116047 on Biotech Values
03/07/11 6:24 PM
don't invest in companies that change their name.
03/07/11 6:28 PM
…don't invest in companies that change their name.
03/07/11 10:10 PM
03/09/11 8:49 AM
12/08/11 1:13 PM
Navidea was chosen as the new name to reflect the Company’s dedication to “NAVigating IDEAs” that translate cutting edge innovation and precision diagnostics technology into novel products to advance patient care.
12/21/11 10:04 AM
…one of my standard rules of biotech investing - don't invest in companies that change their name.
"By overcoming many of the technical obstacles that limited traditional gene medicine approaches, synthetic DNA-based biologics may allow us to optimize the delivery of therapeutic proteins in a safe, controlled and localized fashion never before possible. In turn, this may provide physicians the ability to radically transform the way in which many serious diseases can be treated. I am pleased to be joining the Company, and to be a part of this innovative new effort and area," stated John Monahan , Ph.D., the Company's Senior Vice President of Research & Development.
The Company's ongoing and planned clinical trials of Trimesta™ (estriol) for multiple sclerosis are expected to continue and the Company's planned clinical trial of AEN-100 (modified release zinc) for amyotrophic lateral sclerosis (ALS) is also expected to continue. In addition, the Company intends to seek marketing partners for its marketable zinc-based products reaZin™ and wellZin™.
05/17/14 4:44 PM
…it violates one of my standard rules of biotech investing—don't invest in companies that change their name.
09/03/14 11:15 AM
09/09/14 8:35 AM
Senesco Technologies, Inc. (SNTI)…, a clinical-stage company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, announced today a corporate rebranding under which the Company will change its name to Sevion Therapeutics, Inc. The Company will continue to trade as SNTI until a new ticker symbol is obtained.
09/16/14 11:28 AM
09/08/15 12:37 PM
Trimel Pharmaceuticals Corporation (TRL.TO) today announced that it has changed its corporate name to Acerus Pharmaceuticals Corporation (“Acerus”, pronounced ay-SAIR-us), effective immediately.
“We are very excited to officially launch our new corporate identity with a name that aligns to our Company’s value proposition,” said Tom Rossi, President and Chief Executive Officer of Acerus.
“The name Acerus is derived from the Latin root word acer, and conveys sharp minds and passionate, spirited action as embodied by our current leadership team, employees and partners. Acer is also the genus of trees commonly known as the maple, the official tree and symbol of Canada.”
12/17/15 10:05 AM
12/22/15 12:04 PM
MELA Sciences, Inc. (Nasdaq:MELA), today announced that it will be changing its corporate name to STRATA Skin Sciences, Inc. effective Tuesday, January 5, 2016 and that it will trade under the symbol “SSKN” on the Nasdaq Stock Market.
01/08/16 11:50 AM
03/28/16 1:12 PM
04/18/16 9:57 AM
06/08/16 9:07 AM
06/17/16 10:18 AM
12/05/16 9:07 AM
12/15/16 4:32 PM
06/07/17 4:29 PM
06/27/17 10:03 AM
07/27/17 6:33 PM
10/23/17 2:50 PM
11/20/17 10:43 AM
01/25/18 3:42 PM
05/16/18 12:13 PM
06/22/18 11:04 AM
ALX Oncology is developing ALX148, a high affinity CD47 blocker currently in clinical development (https://www.clinicaltrials.gov/ct2/show/NCT03013218 ).
06/27/18 10:39 AM
07/30/18 11:45 AM
Apricus Biosciences, Inc. announced the signing of a definitive agreement to merge with Seelos Therapeutics, Inc., a privately-held biotechnology company, in an all-stock transaction. The merged company will focus on the development and commercialization of central nervous system (CNS) therapeutics with known mechanisms of action in areas with a highly unmet medical need.
Upon completion of the proposed merger, the name of the merged company will be Seelos Therapeutics, Inc., and the company is expected to begin trading on the Nasdaq Capital Market under the ticker symbol “SEEL.”
…On a pro forma and fully-diluted basis, Seelos shareholders are expected to own approximately 86% of the merged company and current Apricus shareholders are expected to own approximately 14% of the merged company…
09/04/18 3:33 PM
09/28/18 9:34 AM
ITUS Corporation…a biotechnology company focused on using the body's immune system to fight cancer, today announced that on October 1, 2018, the Company will officially change its name to Anixa Biosciences, Inc. Effective at the start of trading on October 1, 2018, the Company's shares will trade on the NASDAQ Capital Market under the new name, and the new stock symbol will be "ANIX."
11/19/18 8:25 AM
Phio Pharmaceuticals Corp. is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA) therapeutic platform.
03/27/19 9:53 AM
04/16/19 11:30 AM
“We are excited about our re-branding and corporate name change reflecting our transition to a gene therapy focused company developing treatments for patients with orphan inherited retinal diseases,” stated Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio.
07/16/19 5:46 PM
01/02/20 10:07 AM
Intrexon Corporation...announced today that it will refocus the company on healthcare, change its name to Precigen, Inc. and, effective immediately, has appointed Helen Sabzevari, PhD, as President and CEO.
The new Precigen will encompass Intrexon's wholly-owned healthcare subsidiaries Precigen, ActoBio Therapeutics, Exemplar Genetics, and its majority ownership interest in Triple-Gene, as well as equity and royalty interests in therapeutics and therapeutic platforms from companies not controlled by Intrexon. Randal J. Kirk has been appointed Executive Chairman.
Additionally, Intrexon has executed binding agreements to sell its smaller non-healthcare businesses for $65.2M plus certain contingent payment rights and entered into an agreement to sell $35M of its common stock. The proceeds from these transactions, combined with the company's cash and short-term investments on hand at December 31, 2019, approximates $175 million thus attaining Intrexon's year-end objective.
03/16/20 10:36 PM
Spherix Incorporated today announced it has completed its name change to AIkido Pharma Inc. and now trades under the ticker "AIKI". The name change reflects company's increased focus on the use of Artificial Intelligence and Machine Learning (AI and ML) in the drug development space.
04/17/20 10:51 AM
05/06/20 11:27 AM
New corporate name, Cardiff Oncology, reflects the Company's mission and commitment to turning the tide on cancer by developing new treatment options for cancer patients…
09/02/20 10:51 AM
10/05/20 9:37 AM
11/10/20 8:59 AM
11/16/20 9:49 AM
AI
